Compare DexCom, Inc. (DXCM) vs Marsh & McLennan Companies, Inc. (MRSH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs Marsh & McLennan Companies, Inc. — how do they compare? DexCom, Inc. trades at $78.49 (market cap $28.06B), while Marsh & McLennan Companies, Inc. trades at $180.51 (market cap $84.90B). The key difference: Marsh & McLennan Companies, Inc. is far larger — about 3× DexCom, Inc.'s market cap, and Marsh & McLennan Companies, Inc. pays a 2.25% dividend while DexCom, Inc. pays none. Which is the better fit depends on your goals.
| DXCM | MRSH | |
|---|---|---|
Market Cap | $28.06B | $84.90B |
Sector | Health | Financials |
52-Week High | $89.53 | $212.28 |
52-Week Low | $54.84 | $157.32 |
Enterprise Value | $27.03B | $105.74B |
Dividend Yield | — | 2.25% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DexCom (DXCM) trades at $74.12, down 2.92% on the day, with a bullish technical signal from moving averages. The company demonstrates strong fundamentals with consistent revenue growth, expanding profit margins, and a track record of beating earnings estimates. Recent regulatory approvals for its G7 15-day CGM in Canada and pediatric clearance for its Stelo OTC system in the U.S. highlight ongoing product expansion.
The investment thesis centers on DexCom's leadership in the growing CGM market, supported by strong financial execution and analyst optimism. Key risks include competition from Abbott, the commercial unproven nature of expansion into non-insulin Type 2 diabetes patients, and potential disruption from GLP-1 drug adoption. The consensus price target of $84.33 suggests ~14% upside from current levels.
Marsh (MRSH) trades at $178.05, down 1.92% on the day, near the analyst consensus low target of $175. The stock shows bullish technical signals with strong moving average support, while recent quarterly earnings have consistently beaten expectations. The company maintains solid profitability with a 14.26% net margin and 27.42% ROE, supported by a 10% dividend increase announced in July 2026. Revenue growth has been steady, reaching $26.98B in 2025, though profit margins show slight compression from previous years.
The outlook remains balanced with strong fundamentals and shareholder returns offset by valuation concerns and rising cost pressures. Investment opportunity centers on consistent earnings beats, dividend growth, and AI initiatives through Oliver Wyman. Key risks include premium valuation multiples, softer insurance pricing tailwinds, and execution challenges in sustaining organic growth as operating expenses rise.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About Marsh & McLennan Companies, Inc.
Marsh & McLennan Companies Inc is a professional services firm that provides advice and solutions in the areas of risk, strategy, and human capital. The company operates through two main segments: risk and insurance services and consulting. In risk and insurance services, the firm offers services via Marsh (an insurance broker) and Guy Carpenter (a risk and reinsurance specialist). The consulting division comprises Mercer (a provider of human resource services) and Oliver Wyman (management and economic consultancy).
Read more on MRSH →
